Maintaining your weight after Mounjaro

Step 1: Recognising when you've arrived at maintenance

The shift from active weight loss to maintenance isn't marked by a single event, it tends to creep up on you. Weight loss slows, then plateaus, and the question becomes whether that plateau is a biological signal that you're at the dose you need, or simply a stall that calls for a different approach.

Your prescriber looks at a few things here. Is your weight genuinely stable across multiple weeks, or is it still drifting downward slowly? Are you at or near the goal you set at the start of treatment? Have you reached your highest tolerated dose, or is there headroom in the titration schedule? The answers shape whether maintenance means holding the current dose, stepping down, or continuing to titrate.

Tirzepatide is licensed in the UK for weight management alongside a reduced-calorie diet and increased physical activity for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, and that licence covers the maintenance phase just as it covers the loss phase. The NHS tirzepatide medicines page has a clear overview of how the medicine works and what ongoing use involves.

One practical note: every repeat order through a regulated private service like ours is clinically re-reviewed before dispatch. That's not a formality. It's the point at which your prescriber considers whether your current dose is still right.

Step 2: Finding the dose that holds rather than reduces

During active weight loss, the goal of titration is to reach the dose that produces the clinical effect, typically working up from 2.5 mg in four-week steps toward whatever dose you tolerate and respond to. Maintenance flips that logic slightly. The question becomes: what is the lowest dose at which your weight stays stable?

For some people, that's 15 mg. For others it's meaningfully lower, and stepping down doesn't mean stepping back. Research and clinical experience both suggest that the dose required to maintain a stable weight is often lower than the peak dose used to lose it, because you're no longer working against an energy surplus. You're simply anchoring what's already been achieved. For those curious about whether the starting dose itself can serve a longer-term purpose, our guidance on using 2.5 mg as a maintenance dose explains the clinical thinking behind that option.

This isn't something to try unilaterally. A maintenance dose decision involves your prescriber reviewing your weight trend, your response to the current dose, any side effects you're still experiencing, and how you feel overall. If you've been wondering specifically whether a lower dose might be right for you, 5 mg as a maintenance dose is a question our clinical team fields regularly, the answer depends on individual response, and is never one-size-fits-all.

The NICE appraisal of tirzepatide (TA1026) notes that if less than 5% body weight is lost after six months at the highest tolerated dose, continuing treatment should be reviewed, a reminder that outcome monitoring is built into good clinical practice throughout.

Step 3: Monitoring and staying clinically supported

Maintenance is not the end of clinical oversight. It's a different kind of oversight, less about dose increases, more about checking in on whether the current plan is still working and whether anything in your health picture has changed.

At this stage, your prescriber wants to know: is your weight holding? Are you getting adequate protein and staying hydrated? Have you had any new symptoms that need attention? Are the lifestyle elements (diet, movement, sleep) still in place? None of these questions have a fixed schedule, but none of them disappear just because you're no longer losing.

For people who reach their goal weight and want to understand what continuing treatment looks like over time, our detailed page on choosing a maintenance dose after reaching your goal weight covers how prescribers approach that conversation and what factors they weigh. Some people remain on maintenance doses indefinitely; others, under clinical guidance, attempt a structured reduction to see how their body responds without the medicine. If you want to understand how the right ongoing dose is determined once active weight loss has ended, our page on finding a Mounjaro maintenance dose after weight loss walks through the clinical considerations in detail.

If you started treatment through a regulated UK online pharmacy, your repeat orders should always come with that clinical re-review, not just a click-to-reorder system. The pen that arrives via DPD, tracked to your door in plain packaging, should reflect a genuine clinical decision, not a subscription default. That distinction matters during maintenance more than at any other stage, because the right dose is less obvious and the risk of just continuing on autopilot is real.

If you stop Mounjaro: what the evidence says

Weight regain after stopping GLP-1 and dual GIP/GLP-1 medicines is well-documented. The biological mechanisms that Mounjaro modulates (appetite signalling, gastric emptying, the brain's response to food cues) tend to revert toward their pre-treatment baseline once the medicine is removed. This isn't a failure of willpower; it's pharmacology.

For people who do stop, the transition needs planning. Abrupt discontinuation without a lifestyle strategy in place carries a higher risk of rapid regain. A structured step-down, combined with sustained dietary and activity habits, gives the body the best chance of holding at least some of the ground it's gained.

If cost is part of the calculation (and it often is during a phase that could extend for years) the treatment options page lays out what's included in a single transparent price, without hidden fees or subscription traps. Understanding the broader range of weight management approaches available can also help frame how Mounjaro fits into a longer-term plan rather than a finite course.

Stopping is a clinical decision, not an administrative one. If you're considering it, raise it with your prescriber before your next repeat, not after.